A prospective international observational prevalence study on prone positioning of ARDS patients: the APRONET (ARDS Prone Position Network) study (Record no. 76461)

MARC details
000 -LEADER
fixed length control field 05673cam a2200169 4500
001 - CONTROL NUMBER
control field NMDX7624
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION
fixed length control field 120401t2018 xxu||||| |||| 00| 0 eng d
100 ## - MAIN ENTRY--PERSONAL NAME
Personal name Kovari, F.
240 ## - UNIFORM TITLE
Uniform title <a href="Intensive Care Medicine">Intensive Care Medicine</a>
245 ## - TITLE STATEMENT
Title A prospective international observational prevalence study on prone positioning of ARDS patients: the APRONET (ARDS Prone Position Network) study
260 ## - PUBLICATION, DISTRIBUTION, ETC. (IMPRINT)
Date of publication, distribution, etc. 2018
500 ## - GENERAL NOTE
General note NMUH Staff Publications
500 ## - GENERAL NOTE
General note 44
520 ## - SUMMARY, ETC.
Summary, etc. &lt;h4 style="font-size: 13px; margin: 0px 0.25em 0px 0px; text-transform: uppercase; float: left; font-family: arial, helvetica, clean, sans-serif; text-align: left;"&gt;&lt;span style="font-size: 10pt;"&gt;INTRODUCTION:&lt;/span&gt;&lt;/h4&gt;&lt;p style="margin: 0px 0px 0.5em; font-size: 1.04em; font-family: arial, helvetica, clean, sans-serif; text-align: left;"&gt;&lt;span style="font-size: 10pt;"&gt;While prone positioning (PP) has been shown to improve patient survival in moderate to severe acute respiratory distress syndrome (ARDS) patients, the rate of application of PP in clinical practice still appears low.&lt;/span&gt;&lt;/p&gt;&lt;h4 style="font-size: 13px; margin: 0px 0.25em 0px 0px; text-transform: uppercase; float: left; font-family: arial, helvetica, clean, sans-serif; text-align: left;"&gt;&lt;span style="font-size: 10pt;"&gt;AIM:&lt;/span&gt;&lt;/h4&gt;&lt;p style="margin: 0px 0px 0.5em; font-size: 1.04em; font-family: arial, helvetica, clean, sans-serif; text-align: left;"&gt;&lt;span style="font-size: 10pt;"&gt;This study aimed to determine the prevalence of use of PP in ARDS patients (primary endpoint), the physiological effects of PP, and the reasons for not using it (secondary endpoints).&lt;/span&gt;&lt;/p&gt;&lt;h4 style="font-size: 13px; margin: 0px 0.25em 0px 0px; text-transform: uppercase; float: left; font-family: arial, helvetica, clean, sans-serif; text-align: left;"&gt;&lt;span style="font-size: 10pt;"&gt;METHODS:&lt;/span&gt;&lt;/h4&gt;&lt;p style="margin: 0px 0px 0.5em; font-size: 1.04em; font-family: arial, helvetica, clean, sans-serif; text-align: left;"&gt;&lt;span style="font-size: 10pt;"&gt;The APRONET study was a prospective international 1-day prevalence study performed four times in April, July, and October 2016 and January 2017. On each study day, investigators in each ICU had to screen every patient. For patients with ARDS, use of PP, gas exchange, ventilator settings and plateau pressure (Pplat) were recorded before and at the end of the PP session. Complications of PP and reasons for not using PP were also documented. Values are presented as median (1st-3rd quartiles).&lt;/span&gt;&lt;/p&gt;&lt;h4 style="font-size: 13px; margin: 0px 0.25em 0px 0px; text-transform: uppercase; float: left; font-family: arial, helvetica, clean, sans-serif; text-align: left;"&gt;&lt;span style="font-size: 10pt;"&gt;RESULTS:&lt;/span&gt;&lt;/h4&gt;&lt;p style="margin: 0px 0px 0.5em; font-size: 1.04em; font-family: arial, helvetica, clean, sans-serif; text-align: left;"&gt;&lt;span style="font-size: 10pt;"&gt;Over the study period, 6723 patients were screened in 141 ICUs from 20 countries (77% of the ICUs were European), of whom 735 had ARDS and were analyzed. Overall 101 ARDS patients had at least one session of PP (13.7%), with no differences among the 4 study days. The rate of PP use was 5.9% (11/187), 10.3% (41/399) and 32.9% (49/149) in mild, moderate and severe ARDS, respectively (P&amp;nbsp;=&amp;nbsp;0.0001). The duration of the first PP session was 18 (16-23) hours. Measured with the patient in the supine position before and at the end of the first PP session, PaO&lt;sub style="line-height: 1.6363em; position: relative; vertical-align: baseline; bottom: -0.25em; top: 0.25em;"&gt;2&lt;/sub&gt;/F&lt;sub style="line-height: 1.6363em; position: relative; vertical-align: baseline; bottom: -0.25em; top: 0.25em;"&gt;I&lt;/sub&gt;O&lt;sub style="line-height: 1.6363em; position: relative; vertical-align: baseline; bottom: -0.25em; top: 0.25em;"&gt;2&lt;/sub&gt;&amp;nbsp;increased from 101 (76-136) to 171 (118-220) mmHg (P&amp;nbsp;=&amp;nbsp;0.0001) driving pressure decreased from 14 [11-17] to 13 [10-16] cmH&lt;sub style="line-height: 1.6363em; position: relative; vertical-align: baseline; bottom: -0.25em; top: 0.25em;"&gt;2&lt;/sub&gt;O (P = 0.001), and Pplat decreased from 26 [23-29] to 25 [23-28] cmH&lt;sub style="line-height: 1.6363em; position: relative; vertical-align: baseline; bottom: -0.25em; top: 0.25em;"&gt;2&lt;/sub&gt;O (P = 0.04). The most prevalent reason for not using PP (64.3%) was that hypoxemia was not considered sufficiently severe. Complications were reported in 12 patients (11.9%) in whom PP was used (pressure sores in five, hypoxemia in two, endotracheal tube-related in two ocular in two, and a transient increase in intracranial pressure in one).&lt;/span&gt;&lt;/p&gt;&lt;h4 style="font-size: 13px; margin: 0px 0.25em 0px 0px; text-transform: uppercase; float: left; font-family: arial, helvetica, clean, sans-serif; text-align: left;"&gt;&lt;span style="font-size: 10pt;"&gt;CONCLUSIONS:&lt;/span&gt;&lt;/h4&gt;&lt;p style="margin: 0px 0px 0.5em; font-size: 1.04em; font-family: arial, helvetica, clean, sans-serif; text-align: left;"&gt;&lt;span style="font-size: 10pt;"&gt;In conclusion, this prospective international prevalence study found that PP was used in 32.9% of patients with severe ARDS, and was associated with low complication rates, significant increase in oxygenation and a significant decrease in driving pressure.&lt;/span&gt;&lt;/p&gt;
856 ## - ELECTRONIC LOCATION AND ACCESS
Uniform Resource Identifier <a href="https://www.ncbi.nlm.nih.gov/pubmed/29218379">https://www.ncbi.nlm.nih.gov/pubmed/29218379</a>
856 ## - ELECTRONIC LOCATION AND ACCESS
Uniform Resource Identifier <a href="http://ferriman.wufoo.com/forms/journal-article-request/">http://ferriman.wufoo.com/forms/journal-article-request/</a>
Holdings
Withdrawn status Lost status Damaged status Not for loan Collection code Home library Current library Shelving location Date acquired Total Checkouts Date last seen Price effective from Koha item type
        Staff publications for NMDX Ferriman information and Library Service (North Middlesex) Ferriman information and Library Service (North Middlesex) Shelves 07/06/2022   07/06/2022 07/06/2022 Book
London Health Libraries Koha Consortium privacy notice